The verifiable place to buy research peptides · Free shipping over $150
0

Research Reference · Growth-Hormone Axis Blend

CJC-1295 + Ipamorelin (Blend)

A two-peptide growth-hormone research blend — CJC-1295 (GHRH receptor) and Ipamorelin (ghrelin receptor), 5 mg of each in one vial.

Last reviewed November 2026 6 peer-reviewed sources 3-minute read

At a glance

CJC-1295 + Ipamorelin combines two peptides that reach growth-hormone release by different routes: CJC-1295, a long-acting analogue of growth-hormone-releasing hormone, and Ipamorelin, a selective growth-hormone secretagogue. Our vials hold 5 mg of each (10 mg in total), and each batch certificate measures both. No study of the combined blend has been published; the evidence belongs to the components.

TypeTwo-peptide blend (10 mg)
ComponentsCJC-1295 5 · Ipamorelin 5 mg
Evidence stageComponent studies (animal + early human)
Human dataNone for the blend

What it’s studied for

GHRH-receptor route

CJC-1295 produced sustained, dose-dependent rises in growth hormone and IGF-1 in healthy adults. 1

Human

Natural pulses kept

Growth hormone was still released in pulses during continuous CJC-1295 stimulation. 2

Human

Ghrelin-receptor route

Ipamorelin released growth hormone without raising ACTH or cortisol. 3

Animal

Ipamorelin pharmacology

Absorption and growth-hormone response modeled in human volunteers. 4

Human

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin (10mg) · $64.99

Third-party tested · batch-matched COA · research use only

View CJC-1295 + Ipamorelin CJC-1295 + Ipamorelin COAs

How it works

The blend pairs two peptides that act on two different receptors in the pituitary. CJC-1295 is built on the first 29 amino acids of growth-hormone-releasing hormone (GHRH) and acts on the GHRH receptor. In its best-known form it binds albumin in the blood, which gave it an extended half-life in rats. 5 In healthy adults it produced sustained, dose-dependent increases in growth hormone and IGF-1, 1 and growth hormone was still released in pulses rather than continuously. 2

Ipamorelin is a five-amino-acid growth-hormone secretagogue that acts on the ghrelin receptor instead. In the study that introduced it, it released growth hormone as selectively as GHRH and did not raise ACTH or cortisol, even at very high doses. 3 Its absorption and growth-hormone response were modeled in human volunteers, 4 and in rats it increased longitudinal bone growth. 6

No study of the two together has been published, so each component’s evidence should be read on its own terms.

Related research

CJC-1295Component · GHRH analogue IpamorelinComponent · GH secretagogue TesamorelinFull-length GHRH analogue

Frequently asked questions

What is in the blend?
CJC-1295 (5 mg) and Ipamorelin (5 mg) in one vial — 10 mg of total peptide.
Why are CJC-1295 and Ipamorelin paired?
They reach growth-hormone release through two different receptors: CJC-1295 through the GHRH receptor, Ipamorelin through the ghrelin receptor.
Has the blend itself been studied?
No published study tests the blend. The research belongs to each component.
How is each batch verified?
The batch certificate of analysis identifies both peptides by mass spectrometry and reports the net content of each. It is published on our COA page.
Is this an approved drug?
No. Neither peptide is an approved drug. For research use only.

Identifiers

Components CJC-1295 (5 mg) + Ipamorelin (5 mg)
Total peptide 10 mg per vial
CJC-1295 GHRH analogue based on hGRF(1-29) · PubChem CID 91971820 · CAS 446262-90-4 — see the CJC-1295 page
Ipamorelin C38H49N9O5 · CAS 170851-70-4 · PubChem CID 9831659
Supplied as Lyophilized (freeze-dried) powder

Component identifiers checked against PubChem (see the CJC-1295 and Ipamorelin pages).

Research timeline

  1. 1998Ipamorelin introduced as the first selective growth-hormone secretagogue. 3
  2. 1999Ipamorelin modeled in human volunteers 4; longitudinal bone growth in rats. 6
  3. 2005CJC-1295 identified as a long-lasting GRF analogue that binds albumin. 5
  4. 2006CJC-1295 studies in healthy adults: prolonged GH and IGF-1 release 1 with pulses preserved. 2

Key studies

StudyModelWhat it found
Teichman 2006 1 Human · healthy adults (CJC-1295) Sustained, dose-dependent GH and IGF-1 increases; half-life 5.8–8.1 days.
Ionescu 2006 2 Human (CJC-1295) Raised trough and mean GH and IGF-1 while preserving GH pulsatility.
Raun 1998 3 Animal (Ipamorelin) GH release as selective as GHRH; no ACTH or cortisol rise even at >200× the effective dose.
Gobburu 1999 4 Human volunteers (Ipamorelin) PK/PD model of ipamorelin disposition and GH response across doses.

Sources

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Teichman SL, et al. J Clin Endocrinol Metab, 2006. Human
  2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Ionescu M, Frohman LA. J Clin Endocrinol Metab, 2006. Human
  3. Ipamorelin, the first selective growth hormone secretagogue. Raun K, et al. Eur J Endocrinol, 1998.
  4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Gobburu JV, et al. Pharm Res, 1999. Human
  5. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Jetté L, et al. Endocrinology, 2005.
  6. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Johansen PB, et al. Growth Horm IGF Res, 1999.
For Research Use Only. This page summarizes published scientific research for educational purposes. It is not medical advice and does not promote, recommend, or describe any human or animal use. Products referenced are sold strictly for laboratory research and are not for human consumption.

Last reviewed November 2026 by Midwest Compounds. Every source above was checked against its original publication.